Familial hypercholesterolaemia in the Malaysian community: Prevalence, under-detection and under-treatment

Familial hypercholesterolaemia in the Malaysian community: Prevalence, under-detection and under-treatment

Aim: Familial hypercholesterolaemia (FH) is the most common autosomal dominant lipid disorder, leading to severe hypercholesterolaemia. Early detection and treatment with lipid-lowering medications may reduce the risk of premature coronary artery disease in FH patients. However, there is scarcity of...

全面介紹

書目詳細資料
發表在:Journal of Atherosclerosis and Thrombosis
主要作者: 2-s2.0-85116887477
格式: Article
語言:English
出版: Japan Atherosclerosis Society 2021
在線閱讀:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85116887477&doi=10.5551%2fjat.57026&partnerID=40&md5=4ce83f091e89dc4ab9aa9a5bf4aa2d1b
id Chua Y.-A.; Razman A.Z.; Ramli A.S.; Mohd Kasim N.A.; Nawawi H.
spelling Chua Y.-A.; Razman A.Z.; Ramli A.S.; Mohd Kasim N.A.; Nawawi H.
2-s2.0-85116887477
Familial hypercholesterolaemia in the Malaysian community: Prevalence, under-detection and under-treatment
2021
Journal of Atherosclerosis and Thrombosis
28
10
10.5551/jat.57026
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85116887477&doi=10.5551%2fjat.57026&partnerID=40&md5=4ce83f091e89dc4ab9aa9a5bf4aa2d1b
Aim: Familial hypercholesterolaemia (FH) is the most common autosomal dominant lipid disorder, leading to severe hypercholesterolaemia. Early detection and treatment with lipid-lowering medications may reduce the risk of premature coronary artery disease in FH patients. However, there is scarcity of data on FH prevalence, detection rate, treatment and control with lipid-lowering therapy in the Malaysian community. Methods: Community participants (n=5130) were recruited from all states in Malaysia. Blood samples were collected for lipid profiles and glucose analyses. Personal and family medical histories were collected by means of assisted questionnaire. Physical examination for tendon xanthomata and premature corneal arcus were conducted on-site. FH were clinically screened using Dutch Lipid Clinic Network Criteria. Results: Out of 5130 recruited community participants, 55 patients were clinically categorised as potential (Definite and Probable) FH, making the prevalence FH among the community as 1:100. Based on current total population of Malaysia (32 million), the estimated number of FH patients in Malaysia is 320,000, while the detection rates are estimated as 0.5%. Lipid-lowering medications were prescribed to 54.5% and 30.5% of potential and possible FH patients, respectively, but none of them achieved the therapeutic LDL-c target. Conclusion: Clinically diagnosed FH prevalence in Malaysian population is much higher than most of the populations in the world. At community level, FH patients are clinically under-detected, with majority of them not achieving target LDL-c level for high-risk patients. Therefore, public health measures are warranted for early detection and treatment, to enhance opportunities for premature CAD prevention. © 2021 Japan Atherosclerosis Society.
Japan Atherosclerosis Society
13403478
English
Article
All Open Access; Gold Open Access; Green Open Access
author 2-s2.0-85116887477
spellingShingle 2-s2.0-85116887477
Familial hypercholesterolaemia in the Malaysian community: Prevalence, under-detection and under-treatment
author_facet 2-s2.0-85116887477
author_sort 2-s2.0-85116887477
title Familial hypercholesterolaemia in the Malaysian community: Prevalence, under-detection and under-treatment
title_short Familial hypercholesterolaemia in the Malaysian community: Prevalence, under-detection and under-treatment
title_full Familial hypercholesterolaemia in the Malaysian community: Prevalence, under-detection and under-treatment
title_fullStr Familial hypercholesterolaemia in the Malaysian community: Prevalence, under-detection and under-treatment
title_full_unstemmed Familial hypercholesterolaemia in the Malaysian community: Prevalence, under-detection and under-treatment
title_sort Familial hypercholesterolaemia in the Malaysian community: Prevalence, under-detection and under-treatment
publishDate 2021
container_title Journal of Atherosclerosis and Thrombosis
container_volume 28
container_issue 10
doi_str_mv 10.5551/jat.57026
url https://www.scopus.com/inward/record.uri?eid=2-s2.0-85116887477&doi=10.5551%2fjat.57026&partnerID=40&md5=4ce83f091e89dc4ab9aa9a5bf4aa2d1b
description Aim: Familial hypercholesterolaemia (FH) is the most common autosomal dominant lipid disorder, leading to severe hypercholesterolaemia. Early detection and treatment with lipid-lowering medications may reduce the risk of premature coronary artery disease in FH patients. However, there is scarcity of data on FH prevalence, detection rate, treatment and control with lipid-lowering therapy in the Malaysian community. Methods: Community participants (n=5130) were recruited from all states in Malaysia. Blood samples were collected for lipid profiles and glucose analyses. Personal and family medical histories were collected by means of assisted questionnaire. Physical examination for tendon xanthomata and premature corneal arcus were conducted on-site. FH were clinically screened using Dutch Lipid Clinic Network Criteria. Results: Out of 5130 recruited community participants, 55 patients were clinically categorised as potential (Definite and Probable) FH, making the prevalence FH among the community as 1:100. Based on current total population of Malaysia (32 million), the estimated number of FH patients in Malaysia is 320,000, while the detection rates are estimated as 0.5%. Lipid-lowering medications were prescribed to 54.5% and 30.5% of potential and possible FH patients, respectively, but none of them achieved the therapeutic LDL-c target. Conclusion: Clinically diagnosed FH prevalence in Malaysian population is much higher than most of the populations in the world. At community level, FH patients are clinically under-detected, with majority of them not achieving target LDL-c level for high-risk patients. Therefore, public health measures are warranted for early detection and treatment, to enhance opportunities for premature CAD prevention. © 2021 Japan Atherosclerosis Society.
publisher Japan Atherosclerosis Society
issn 13403478
language English
format Article
accesstype All Open Access; Gold Open Access; Green Open Access
record_format scopus
collection Scopus
_version_ 1828987869318873088

相似書籍

  • Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
    由: 2-s2.0-85053666909
    出版: (2018)
  • Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
    由: Vallejo-Vaz A.J.; Stevens C.A.T.; Lyons A.R.M.; Dharmayat K.I.; Freiberger T.; Hovingh G.K.; Mata P.; Raal F.J.; Santos R.D.; Soran H.; Watts G.F.; Abifadel M.; Aguilar-Salinas C.A.; Alhabib K.F.; Alkhnifsawi M.; Almahmeed W.; Alnouri F.; Alonso R.; Al-Rasadi K.; Al-Sarraf A.; Al-Sayed N.; Araujo F.; Ashavaid T.F.; Banach M.; Béliard S.; Benn M.; Binder C.J.; Bogsrud M.P.; Bourbon M.; Chlebus K.; Corral P.; Davletov K.; Descamps O.S.; Durst R.; Ezhov M.; Gaita D.; Genest J.; Groselj U.; Harada-Shiba M.; Holven K.B.; Kayikcioglu M.; Khovidhunkit W.; Lalic K.; Latkovskis G.; Laufs U.; Liberopoulos E.; Lima-Martinez M.M.; Lin J.; Maher V.; Marais A.D.; März W.; Mirrakhimov E.; Miserez A.R.; Mitchenko O.; Nawawi H.; Nordestgaard B.G.; Panayiotou A.G.; Paragh G.; Petrulioniene Z.; Pojskic B.; Postadzhiyan A.; Raslova K.; Reda A.; Reiner Ž.; Sadiq F.; Sadoh W.E.; Schunkert H.; Shek A.B.; Stoll M.; Stroes E.; Su T.-C.; Subramaniam T.; Susekov A.V.; Tilney M.; Tomlinson B.; Truong T.H.; Tselepis A.D.; Tybjærg-Hansen A.; Cárdenas A.V.; Viigimaa M.; Wang L.; Yamashita S.; Tokgozoglu L.; Catapano A.L.; Ray K.K.
    出版: (2021)
  • Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
    由: Vallejo-Vaz A.J.; Marco M.D.; Stevens C.A.T.; Akram A.; Freiberger T.; Hovingh G.K.; Kastelein J.J.P.; Mata P.; Raal F.J.; Santos R.D.; Soran H.; Watts G.F.; Abifadel M.; Aguilar-Salinas C.A.; Al-Khnifsawi M.; Alkindi F.A.; Alnouri F.; Alonso R.; Al-Rasadi K.; Al-Sarraf A.; Ashavaid T.F.; Binder C.J.; Bogsrud M.P.; Bourbon M.; Bruckert E.; Chlebus K.; Corral P.; Descamps O.; Durst R.; Ezhov M.; Fras Z.; Genest J.; Groselj U.; Harada-Shiba M.; Kayikcioglu M.; Lalic K.; Lam C.S.P.; Latkovskis G.; Laufs U.; Liberopoulos E.; Lin J.; Maher V.; Majano N.; Marais A.D.; März W.; Mirrakhimov E.; Miserez A.R.; Mitchenko O.; Nawawi H.M.; Nordestgaard B.G.; Paragh G.; Petrulioniene Z.; Pojskic B.; Postadzhiyan A.; Reda A.; Reiner Ž.; Sadoh W.E.; Sahebkar A.; Shehab A.; Shek A.B.; Stoll M.; Su T.-C.; Subramaniam T.; Susekov A.V.; Symeonides P.; Tilney M.; Tomlinson B.; Truong T.-H.; Tselepis A.D.; Tybjærg-Hansen A.; Vázquez-Cárdenas A.; Viigimaa M.; Vohnout B.; Widén E.; Yamashita S.; Banach M.; Gaita D.; Jiang L.; Nilsson L.; Santos L.E.; Schunkert H.; Tokgözoğlu L.; Car J.; Catapano A.L.; Ray K.K.; Schreier L.; Pang J.; Dieplinger H.; Hanauer-Mader G.; Desutter J.; Langlois M.; Mertens A.; Rietzschel E.; Wallemacq C.; Isakovic D.; Dzankovic A.M.; Obralija J.; Pojskic L.; Sisic I.; Stimjanin E.; Torlak V.A.; Jannes C.E.; Krieger J.E.; Pereira A.C.; Ruel I.; Asenjo S.; Cuevas A.; Pećin I.; Miltiadous G.; Panayiotou A.G.; Vrablik M.; Benn M.; Heinsar S.; Béliard S.; Gouni-Berthold I.; Hengstenberg W.; Julius U.; Kassner U.; Klose G.; König C.; König W.; Otte B.; Parhofer K.; Schatz U.; Schmidt N.; Steinhagen-Thiessen E.; Vogt A.; Antza C.; Athyros V.; Bilianou E.; Boufidou A.; Chrousos G.; Elisaf M.; Garoufi A.; Katsiki N.; Kolovou G.; Kotsis V.; Rallidis L.; Rizos C.; Skalidis E.; Skoumas I.; Tziomalos K.; Shawney J.P.S.; Abbaszadegan M.R.; Aminzadeh M.; Hosseini S.; Mobini M.; Vakili R.; Zaeri H.; Agar R.; Boran G.; Colwell N.; Crowley V.; Durkin M.; Griffin D.; Kelly M.; Rakovac-Tisdall A.; Bitzur R.; Cohen H.; Eliav O.; Ellis A.; Gavish D.; Harats D.; Henkin Y.; Knobler H.; Leavit L.; Leitersdorf E.; Schurr D.; Shpitzen S.; Szalat A.; Arca M.; Averna M.; Bertolini S.; Calandra S.; Tarugi P.; Erglis A.; Gilis D.; Nesterovics G.; Saripo V.; Upena-Roze A.; Elbitar S.; Jambart S.; Khoury P.E.; Gargalskaite U.; Kutkiene S.; Al-Khateeb A.; An C.Y.; Ismail Z.; Kasim S.; Ibrahim K.S.; Radzi A.B.M.; Kasim N.A.; Nor N.S.M.; Ramli A.S.; Razak S.A.; Muid S.; Rosman A.; Sanusi A.R.; Razman A.Z.; Nazli S.A.; Kek T.L.; Azzopardi C.; Galán G.; Rubinstein A.; Magaña-Torres M.T.; Martagon A.; Mehta R.; Wittekoek M.E.; Isara A.R.; Obaseki D.E.; Ohenhen O.A.; Holven K.B.; Gruchała M.; Baranowska M.; Borowiec-Wolny J.; Gilis-Malinowska N.; Michalska-Grzonkowska A.; Pajkowski M.; Parczewska A.; Romanowska-Kocejko M.; Stróżyk A.; Żarczyńska-Buchowiecka M.; Kleinschmidt M.; Alves A.C.; Medeiros A.M.; Ershova A.; Korneva V.; Kuznetsova T.; Malyshev P.; Meshkov A.; Rozhkova T.; Popovic L.; Lukac S.S.; Stosic L.; Rasulic I.; Lalic N.M.; Chua T.S.J.; Ting S.P.L.; Raslova K.; Battelino T.; Cevc M.; Jug B.; Kovac J.; Podkrajsek K.T.; Sustar U.; Trontelj K.J.; Marais D.; Isla L.P.; Martin F.J.; Charng M.-J.; Chen P.-L.; Dell’oca N.; Fernández G.; Ressia A.; Reyes X.; Zelarayan M.; Alieva R.B.; Hoshimov S.U.; Nizamov U.I.; Kurbanov R.D.; Lima-Martínez M.M.; Nguyen M.-N.T.; Do D.-L.; Kim N.-T.; Le T.-T.; Le H.-A.
    出版: (2018)
  • Prevalence and severity of Bertolotti’s syndrome in Malaysia: A common under diagnosis
    由: Noorman M.F.; Sofian A.A.; Kandar M.K.; Halim A.H.A.; Harun M.H.; Ramlee F.A.M.; Hamzah F.C.; Rahim E.A.
    出版: (2022)
  • Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration
    由: 2-s2.0-85006713689
    出版: (2016)